US Patent

US12508313 — Quinoline derivative-containing pharmaceutical composition

Formulation · Assigned to Eisai R&D Management Co Ltd · Expires 2030-10-04 · 4y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing a quinoline derivative compound or its salt or solvate, used as a tumor preventive or therapeutic agent.

USPTO Abstract

A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof; and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: wherein, R 1 is a hydrogen atom, a C 1-6 alkyl group or a C 3-8 cycloalkyl group; and R 2 is a hydrogen atom or a methoxy group.

Drugs covered by this patent

Patent Metadata

Patent number
US12508313
Jurisdiction
US
Classification
Formulation
Expires
2030-10-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.